



Substitute for form 1449A/PTO

Complete if Known

(use as many sheets as necessary)

Sheet	1	of	2
-------	---	----	---

Application Number	09/842111
Filing Date	April 26, 2001
First Named Inventor	Kathleen Danenberg
Group Art Unit	1632
Examiner Name	To be assigned
Attorney Docket Number	11220/128

TECH CENTER 1600/2300

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.



PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 2 of 2

Complete if Known

Application Number	09/842111
Filing Date	April 26, 2001
First Named Inventor	Kathleen Danenberg
Group Art Unit	1632
Examiner Name	To be assigned
Attorney Docket Number	11220/128

RECEIVED

MAR 08 2002

TECH CENTER 1600/2900

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
✓	1	I. Miyauchi, et al., "Further study of hepatitis C virus RNA detection in formalin -fixed, paraffin -embedded liver tissues by ligation -dependent polymerase chain reaction" Pathology International 1998:48: 428-432	
✓	2	J. Grem et al., "Thymidine kinase, thymidylate synthase, and dihydropyrimidine dehydrogenase profiles of cell lines of the National Cancer Institute's anticancer drug screen" Clinical Cancer Research, Vol. 7, 999-1009, April 2001	

Examiner
SignatureDate
Considered

7/31/02

¹ EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.